Opdivo Qvantig (nivolumab/hyaluronidase-nvhy) is a prescription drug used to treat certain types of cancer. Opdivo Qvantig comes as a liquid that’s injected under your skin. Opdivo Qvantig is used in ...
Doctors in India are increasingly exploring “dose optimisation” to make expensive treatments more affordable while also reducing side-effects, and new findings from Tata Memorial Hospital highlight ...
The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved median ...
A groundbreaking study from Tata Memorial Hospital shows that using ultra-low doses of nivolumab, an immunotherapy drug, can effectively treat cancer while drastically reducing costs by 90%. This ...
For patients with stage III melanoma, the median duration of distant metastasis-free survival was more than 9 years and 83.8 months with nivolumab and ipilimumab, respectively. HealthDay News — For ...
Nivolumab and ipilimumab combination approved for microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC), showing significant progression-free ...
Please provide your email address to receive an email when new articles are posted on . First-line treatment with nivolumab-ipilimumab improved PFS and response compared with monotherapy for certain ...
Immune landscape in lung cancer: Lymphocyte subsets as potential predictors of treatment outcomes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...
Assessment of time-to-treatment-failure (TTF) as a surrogate endpoint for overall survival (OS) to immune checkpoint inhibitor (ICI) regimens in metastatic renal cell carcinoma (mRCC): Findings from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results